More Than Half of U.S. Adults Could Be Candidates for Ozempic

Ozempic Insulin box and injection pen or insulin cartridge pen for diabetes patients from Novo Nordisk. Blurred pharmacy background

Key Takeaways

  • A new tally finds that nearly half of the U.S. adult population might be eligible to take semaglutide to battle obesity, diabetes or heart disease

  • At nearly $1,000 per month, the bigger question is who would pay for the drug

  • Currently, insurance typically only covers the medication for those diagnosed with type 2 diabetes

Recommended for you

Originally published on healthday.com, part of the BLOX Digital Content Exchange.

(0) comments

Welcome to the discussion.

Please log in, or sign up for a new, free account to read or post comments.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.